注射毒品的男性和女性对注射和口服PrEP预防艾滋病毒的兴趣。

IF 3.2 3区医学 Q1 SUBSTANCE ABUSE

Journal of Addiction Medicine Pub Date : 2025-07-01 Epub Date: 2025-02-03 DOI:10.1097/ADM.0000000000001440

Elenore P Bhatraju, Judith I Tsui, Moonseong Heo, Laksika B Sivaraj, Snehal S Lopes, Shruti Mehta, Paula Lum, Lynn E Taylor, Judith Feinberg, Arthur Kim, Brianna Norton, Irene Pericot-Valverde, Kimberly A Page, Alain H Litwin

{"title":"注射毒品的男性和女性对注射和口服PrEP预防艾滋病毒的兴趣。","authors":"Elenore P Bhatraju, Judith I Tsui, Moonseong Heo, Laksika B Sivaraj, Snehal S Lopes, Shruti Mehta, Paula Lum, Lynn E Taylor, Judith Feinberg, Arthur Kim, Brianna Norton, Irene Pericot-Valverde, Kimberly A Page, Alain H Litwin","doi":"10.1097/ADM.0000000000001440","DOIUrl":null,"url":null,"abstract":"Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited. This study evaluated interest and concerns around oral and injectable PrEP among PWID based on gender.Methods: This cross-sectional analysis of survey data from 8 sites in the United States (n = 284) assessed attitudes and interest in PrEP. Demographics, HIV risk behaviors, and attitudes toward PrEP were described overall and by self-identified gender (female vs male).Results: Participants completed the PrEP survey between 2019 and 2021. The mean (standard deviation) age was 44.6 (11.4) years, 29% female, and 66% White. Mean self-perceived HIV risk score (0-10) was 2.3 (standard deviation 2.0). Interest in injectable PrEP (49.5%) was significantly higher than interest in daily oral PrEP (20.1%) ( P ≤ 0.001). The most cited concerns were medication side effects (53%) and medication interactions (39.2%). Perceived HIV risk and PrEP concerns were not significantly different between genders.Conclusions: There was high interest in injectable PrEP, particularly among females. The top concerns were medication side effects and medication interactions. These results suggest high acceptability of injectable PrEP among PWID. Future research could explore the advantages identified by female participants as well as implementation strategies for access and uptake among this vulnerable population.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"479-483"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310360/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs.\",\"authors\":\"Elenore P Bhatraju, Judith I Tsui, Moonseong Heo, Laksika B Sivaraj, Snehal S Lopes, Shruti Mehta, Paula Lum, Lynn E Taylor, Judith Feinberg, Arthur Kim, Brianna Norton, Irene Pericot-Valverde, Kimberly A Page, Alain H Litwin\",\"doi\":\"10.1097/ADM.0000000000001440\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited. This study evaluated interest and concerns around oral and injectable PrEP among PWID based on gender.Methods: This cross-sectional analysis of survey data from 8 sites in the United States (n = 284) assessed attitudes and interest in PrEP. Demographics, HIV risk behaviors, and attitudes toward PrEP were described overall and by self-identified gender (female vs male).Results: Participants completed the PrEP survey between 2019 and 2021. The mean (standard deviation) age was 44.6 (11.4) years, 29% female, and 66% White. Mean self-perceived HIV risk score (0-10) was 2.3 (standard deviation 2.0). Interest in injectable PrEP (49.5%) was significantly higher than interest in daily oral PrEP (20.1%) ( P ≤ 0.001). The most cited concerns were medication side effects (53%) and medication interactions (39.2%). Perceived HIV risk and PrEP concerns were not significantly different between genders.Conclusions: There was high interest in injectable PrEP, particularly among females. The top concerns were medication side effects and medication interactions. These results suggest high acceptability of injectable PrEP among PWID. Future research could explore the advantages identified by female participants as well as implementation strategies for access and uptake among this vulnerable population.\",\"PeriodicalId\":14744,\"journal\":{\"name\":\"Journal of Addiction Medicine\",\"volume\":\" \",\"pages\":\"479-483\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310360/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Addiction Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ADM.0000000000001440\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ADM.0000000000001440","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

摘要

背景：注射吸毒者（PWID）感染人类免疫缺陷病毒（HIV）的风险增加。注射的妇女是一个特别脆弱的群体。暴露前预防（PrEP）是有效的，但获取和吸收有限。本研究基于性别评估了PWID患者对口服和注射PrEP的兴趣和关注。方法：对来自美国8个站点（n = 284）的调查数据进行横断面分析，评估对PrEP的态度和兴趣。人口统计学、艾滋病毒风险行为和对PrEP的态度进行总体描述，并按自我认定的性别（女性与男性）进行描述。结果：参与者在2019年至2021年期间完成了PrEP调查。平均（标准差）年龄为44.6（11.4）岁，女性占29%，白人占66%。平均自我感知艾滋病毒风险评分（0-10）为2.3分（标准差2.0）。对注射PrEP的兴趣（49.5%）显著高于对每日口服PrEP的兴趣（20.1%）（P≤0.001）。最常见的担忧是药物副作用（53%）和药物相互作用（39.2%）。感知艾滋病毒风险和PrEP关注在性别之间没有显著差异。结论：人们对注射PrEP有很高的兴趣，尤其是女性。最令人担忧的是药物副作用和药物相互作用。提示PWID患者可接受性较高。未来的研究可以探索女性参与者确定的优势，以及在这一弱势群体中获取和吸收的实施策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs.

Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited. This study evaluated interest and concerns around oral and injectable PrEP among PWID based on gender.

Methods: This cross-sectional analysis of survey data from 8 sites in the United States (n = 284) assessed attitudes and interest in PrEP. Demographics, HIV risk behaviors, and attitudes toward PrEP were described overall and by self-identified gender (female vs male).

Results: Participants completed the PrEP survey between 2019 and 2021. The mean (standard deviation) age was 44.6 (11.4) years, 29% female, and 66% White. Mean self-perceived HIV risk score (0-10) was 2.3 (standard deviation 2.0). Interest in injectable PrEP (49.5%) was significantly higher than interest in daily oral PrEP (20.1%) ( P ≤ 0.001). The most cited concerns were medication side effects (53%) and medication interactions (39.2%). Perceived HIV risk and PrEP concerns were not significantly different between genders.

Conclusions: There was high interest in injectable PrEP, particularly among females. The top concerns were medication side effects and medication interactions. These results suggest high acceptability of injectable PrEP among PWID. Future research could explore the advantages identified by female participants as well as implementation strategies for access and uptake among this vulnerable population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Addiction Medicine 医学-药物滥用

CiteScore

6.10

自引率

9.10%

发文量

260

审稿时长

>12 weeks

期刊介绍： The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including: •addiction and substance use in pregnancy •adolescent addiction and at-risk use •the drug-exposed neonate •pharmacology •all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances •diagnosis •neuroimaging techniques •treatment of special populations •treatment, early intervention and prevention of alcohol and drug use disorders •methodological issues in addiction research •pain and addiction, prescription drug use disorder •co-occurring addiction, medical and psychiatric disorders •pathological gambling disorder, sexual and other behavioral addictions •pathophysiology of addiction •behavioral and pharmacological treatments •issues in graduate medical education •recovery •health services delivery •ethical, legal and liability issues in addiction medicine practice •drug testing •self- and mutual-help.